Genomic biomarkers predict response to combined ATR inhibition and radiotherapy.

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2024-10-18 DOI:10.1158/1078-0432.ccr-24-2306

Benjamin R Schrank,Lauren E Colbert

引用次数: 0

Abstract

For decades, chemoradiosensitization with checkpoint kinase inhibitors has been proposed but largely unexplored. A recent study reports the novel ATR kinase inhibitor, RP-3500, synergizes with radiation to control Atm-/- tumors in vivo. RP-3500 did not radiosensitize wild-type or Brca-1 deficient tumors, highlighting the need for a genotype-tailored approach.

查看原文本刊更多论文

基因组生物标志物可预测对联合 ATR 抑制和放疗的反应。

几十年来，利用检查点激酶抑制剂进行化疗放射增敏的方法一直被提出，但大多尚未得到探索。最近的一项研究报告称，新型ATR激酶抑制剂RP-3500与辐射协同控制体内Atm-/-肿瘤。RP-3500不能使野生型或Brca-1缺陷型肿瘤放射致敏，这突出表明需要一种针对基因型的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.